ClinicalTrials.gg
CompletedNCT01226602Updated Feb 13, 2012

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

A Phase 1 interventional study of AZD6140 and Placebo in Blood Flow Speed and Coronary Flow Velocity, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

02

Conditions studied

  • Blood Flow Speed
  • Coronary Flow Velocity

Keywords

  • Ticagrelor
  • Healthy
  • Coronary flow velocity
  • Adenosine
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suitable for recording of CBFV and have no adverse reaction to adenosine challenge
  • Have a between 18 and 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of disease or disorder.
  • Abnormal vital signs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    1

    Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder

    Drug: AZD6140

  • Placebo comparator
    2

    Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder

    Drug: Placebo

Interventions

  • P2Y12 receptor antagonist

    Also known as: Ticagrelor

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug.

    Time frame: During 6 h at visit 2

  2. Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug.

    Time frame: During 6 h at visit 3

Secondary outcomes

  1. Effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity by estimating the change in area under the adenosine dose response curve before and after infusion of theophylline.

    Time frame: During 6 h at visit 2

  2. Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline.

    Time frame: During 6h at visit 2

  3. Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline.

    Time frame: During 6 h at visit 3

07

Study locations

1 site
  • Research Site
    Uppsala, Sweden
08

References and documents

Publications

  • Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. doi: 10.1016/j.jacc.2012.11.032. Epub 2013 Jan 9. PubMed 23312702 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2010
First posted
Oct 22, 2010
Start
Dec 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Feb 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01226602
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 22, 2010
Start date
Dec 2010
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Feb 13, 2012

Study contacts

Jay Horrow, MD
study director · AstraZeneca
Marianne Hartford, MD
principal investigator · CTC, Göteborg
Mirjana Kujacic, MD PhD
study chair · AstraZeneca, Mölndal Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion